We also took the decision to combine evidence from animal and human studies to explore the evidence from cancer studies that examined the effects of CB1/2 modulation on a wide range of pain indices using a variety of approaches, namely administration of pharmacological agents, genetic knockout of gene in animals, and manipulation of gene, Ribonucleic acid (RNA) and protein expression in patients. This evidence concerns the gene CNR1 and cancer.